Global gout disease treatment market is estimated to witness high growth, owing to increasing prevalence of gout and rising demand for Allopurinol alternatives
Global gout disease treatment market is estimated to be valued at USD 2.81 Bn in 2024, exhibiting a CAGR of 8.1% over the forecast period of 2024-2031. Furthermore, rising geriatric population who are more prone to developing gout can drive the market growth.
Market Dynamics:
Global gout disease treatment market growth is primarily driven by increasing prevalence of gout and rising demand for alternative drugs to allopurinol. Gout is the most common form of inflammatory arthritis affecting millions of people worldwide. According to recent studies, around 4% of adults in the U.S. suffer from gout at some point in their lifetime. Rising geriatric population who are more susceptible to developing gout can also drive the market growth. Limitations and adverse effects associated with the long-term usage of allopurinol have boosted demand for alternative therapeutic options for gout treatment. Companies are increasingly investing in R&D to develop novel drugs with improved efficacy and safety profiles. This can drive the market growth over the forecast period.
Increasing Prevalence of Hyperuricemia and Gout Disease Global gout disease treatment market growth is driven by rising prevalence of hyperuricemia and gout disease across the globe. According to recent studies, nearly 30 million people in the U.S. suffer from hyperuricemia. Moreover, gout is considered as the most common form of inflammatory arthritis, affecting over 8 million Americans alone. Factors such as the adoption of unhealthy lifestyles, consumption of purine-rich diets, increasing alcohol intake, and rising obesity rates contribute to rising gout disease burden. As gout has no cure, lifelong treatment and management are required, thus, boosting demand for drugs and therapies for its treatment.
Growing Geriatric Population
Growing geriatric population worldwide who are at a higher risk of developing hyperuricemia and gout can drive the market growth. Advanced age is a significant risk factor for gout due to reduced renal function and increased inflammation levels. According to the UN Population Fund, the number of people aged 60 years or above will double by 2050 to reach nearly 2.1 billion. Countries with large aging populations such as the U.S., China, Japan, and those across Europe will witness increase in the number of gout patients globally. This demographic shift can boost demand for gout treatment medications among the elderly population.
Poor Compliance to Medication and Treatment Regimens Poor patient compliance to long-term medications and treatment regimens can hamper the market growth. Gout often requires lifelong treatment but maintaining adherence to dietary restrictions and daily medications proves difficult for many patients. Non-compliance reduces treatment effectiveness and increases the risk of recurring gout attacks. Some common reasons for non-adherence include complex dosing instructions, medication side effects, cost issues, polypharmacy challenges, and others. This acts as a barrier to optimal treatment outcomes and limits revenue opportunities for drug manufacturers.
High Treatment Costs Pose Significant Barrier in Developing Nations
High cost of gout treatment medications and specialized therapy procedures can hamper the market growth in developing nations. Some biologic drugs used as last resort options can cost over US$ 100,000 annually in certain countries. Moreover, procedures like urate-lowering surgery are often not covered by public health insurances in low and middle-income countries. The high out-of-pocket costs make treatment unaffordable for most patients living in poverty. This restricts proper access to standard gout management options in developing regions of Asia Pacific and Latin America.
Growing Development of Novel Drug Classes Offers Lucrative Opportunities
Development of new and innovative drug classes to treat gout more effectively can offer growth opportunities for the market players. There is much research focus on developing urate-lowering agents beyond xanthine oxidase inhibitors. Some promising new molecules under clinical trials include URAT1 inhibitors, SLC22A12 inhibitors, and others. These novel therapies have potential to surpass existing drugs in terms of efficiency and safety profiles. This developing R&D pipeline will offer future market revenues from premium-priced specialty drugs.
Increasing Adoption of Combination Therapies
Rising popularity of combination drug therapies for gout treatment can also offer growth opportunities. Combining urate-lowering medications with anti-inflammatory agents is gaining acceptance as an efficient treatment strategy. It helps address both hyperuricemia and inflammation concurrently for faster symptom relief. The multi-drug regimen improves compliance as well. This presents an attractive opportunity for collaborative drug development between pharma giants. Global gout therapeutics market can gain from innovations in drug combinations catering to unmet needs of gout patients worldwide.
Link: https://www.coherentmarketinsights.com/market-insight/gout-disease-treatment-market-3082
Key Developments
- In March 2023, ProtalixBioTherapeutics, Inc., a biopharmaceutical firm specializing in developing, manufacturing, and marketing recombinant therapeutic proteins using its ProCellEx plant cell–based protein expression system, initiated dosing of the first patient in its phase I First in Human (FIH) clinical trial for PRX-115. PRX-115 is Protalix's recombinant PEGylated uricase product candidate aimed at potentially treating severe cases of gout.
- In March 2023, Selecta Biosciences, Inc, a biotechnology company, and Sobi, a pharmaceutical company, announced positive results from the Phase 3 DISSOLVE I & II trials evaluating SEL-212 in adult patients with chronic refractory gout. DISSOLVE I (the "US Study") met its primary endpoint, with 56% of patients receiving monthly doses achieving a response of maintaining serum urate levels below 6 mg/dL for at least 80% of the time during month six.
- In March 2022, Atom Bioscience reported favorable outcomes from a Phase 2a clinical trial for ABP-671, a treatment for chronic gout, conducted under randomized double-blind, placebo-controlled conditions
- In March 2022, the U.S. Food and Drug Administration granted approval for Strides Pharma's 0.6 mg Colchicine tablets USP, indicated for the treatment and prevention of gout
Key Players: Takeda Pharmaceutical Company Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., AstraZeneca plc, Horizon Therapeutics plc, Merck & Co. Inc., Teijin Pharma Ltd., GlaxoSmithKline, Plc., Zydus Group, Menarini Group, JW Pharmaceutical,Simcere Pharmaceutical Group, Ionis Pharmaceuticals, Inc., Selecta Biosciences, Mylan N.V.
